Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Hyperimmune Globulins Market Growth Potential: How Will Market Size Change Through 2030?
The global market for hyperimmune globulins has experienced significant expansion lately, with projections indicating continued robust growth. It is estimated to increase from a value of $2.06 billion in 2025 to $2.21 billion in 2026, reflecting a compound annual growth rate of 7.6%. This historical growth trend was fueled by several key factors, including the established efficacy of these products in preventing rabies and tetanus, a rising prevalence of infectious diseases, a considerable dependence on therapies derived from blood plasma, various government-led immunization initiatives, and the expansion of emergency medical services within hospital settings.
The hyperimmune globulins sector anticipates substantial expansion in the forthcoming years, projecting a market valuation of $2.86 billion by 2030 with a compound annual growth rate (CAGR) of 6.7%. This anticipated growth during the forecast period is fueled by several key factors, including an uptick in organ transplantation procedures, a rise in viral infection occurrences, a broader development of plasma donation facilities, improvements in purification methodologies, and an intensified emphasis on swift immune protection. Prominent trends anticipated in this timeframe encompass a heightened demand for passive immunization treatments, augmented utilization for post-exposure prophylaxis, escalating adoption within transplant and immunocompromised patient care, an expansion of plasma collection and fractionation capabilities, and a reinforcement of regulatory supervision and quality benchmarks.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16448&type=smp
Hyperimmune Globulins Market Expansion Drivers: What Is Shaping Future Growth?
The expansion of the hyperimmune globulin market is anticipated to be driven by the escalating occurrence of infectious diseases, which are illnesses caused by harmful agents like viruses, bacteria, fungi, and parasites. Factors such as antimicrobial resistance, shifts in climate, and population increase contribute to the growing spread of these diseases. Hyperimmune globulins play a crucial role in managing infectious diseases by providing prompt passive immunity through the administration of concentrated antibodies targeting specific pathogens, thereby assisting in the prevention or treatment of conditions like rabies, hepatitis B, and tetanus. Illustrating this trend, a report from the UK Health Security Agency in August 2024 indicated that the West Midlands region in the UK recorded the highest number of measles cases in 2023, with 160 instances (44%), closely followed by London with 122 cases (33%). Notably, a substantial majority of these cases, 232 in total (63%), involved children under the age of 10. Measles activity saw a marked surge toward the year’s end, with 157 new cases reported in December, a significant increase from the 45 cases observed in November, underscoring the rising prevalence of infectious diseases and its consequent impact on the hyperimmune globulin market.
Government-backed initiatives focused on healthcare research and development are poised to be a key catalyst for the hyperimmune globulin market’s advancement. The escalating need for novel medical solutions and the imperative to address evolving health concerns are fueling a rise in these governmental R&D efforts. Such initiatives are instrumental in fostering the development and broader availability of hyperimmune globulins, offering a robust means to combat specific infectious diseases effectively. As an example, the Office for National Statistics in the UK, a government department, reported in May 2024 that overall healthcare spending experienced a nominal increase of 5.6% between 2022 and 2023, representing a considerable acceleration compared to the 0.9% growth registered in the preceding year. Consequently, the robust support from governmental research and development programs is a significant driver for the hyperimmune globulin market.
The hyperimmune globulin market is projected for growth, largely influenced by the increasing number of autoimmune disease diagnoses and the resulting heightened demand for antibody-based immune modulation therapies. Autoimmune diseases, characterized by the immune system’s aberrant attack on the body’s own healthy tissues, are becoming more prevalent, potentially due to increased exposure to environmental factors like pollution and chemicals. Hyperimmune globulins serve a therapeutic role in these conditions by delivering targeted antibodies that help regulate improper immune responses. To illustrate, data from Public Health Scotland, a national organization, revealed in August 2024 that the Scottish Multiple Sclerosis Register (SMSR) documented 455 new cases of Multiple Sclerosis in 2023, highlighting the growing burden of autoimmune diseases and consequently bolstering the hyperimmune globulin market.
Hyperimmune Globulins Market Segment Breakdown: Which Categories Generate The Most Revenue?
The hyperimmune globulins market covered in this report is segmented –
1) By Type: Hepatitis B Hyperimmune Globulin, Rabies Hyperimmune Globulin, Tetanus Hyperimmune Globulin, Cytomegalovirus (CMV) Hyperimmune Globulin, Varicella-Zoster Virus (VZV) Hyperimmune Globulin, Respiratory Syncytial Virus (RSV) Hyperimmune Globulin, Other Types
2) By Route Of Administration: Intramuscular, Intravenous
3) By Application: Government Institution, Private Sector, Other Applications
Subsegments:
1) By Hepatitis B Hyperimmune Globulin: Intramuscular Hepatitis B Hyperimmune Globulin, Intravenous Hepatitis B Hyperimmune Globulin
2) By Rabies Hyperimmune Globulin: Rabies Immune Globulin (Human), Rabies Immune Globulin (Equine)
3) By Tetanus Hyperimmune Globulin: Tetanus Immune Globulin (Human), Tetanus Immune Globulin (Equine)
4) By Cytomegalovirus (Cmv) Hyperimmune Globulin: Cmv Immune Globulin For Organ Transplantation, Cmv Immune Globulin For Neonatal Infection
5) By Varicella-Zoster Virus (Vzv) Hyperimmune Globulin: Vzv Immune Globulin For Post-Exposure Prophylaxis, Vzv Immune Globulin For Immunocompromised Patients
6) By Respiratory Syncytial Virus (Rsv) Hyperimmune Globulin: Rsv Immune Globulin For Infants And Children, Rsv Immune Globulin For Adults With Respiratory Conditions
7) By Other Types: Diphtheria Hyperimmune Globulin, Botulism Hyperimmune Globulin, Other Specialized Hyperimmune Globulins
Hyperimmune Globulins Market Key Players And Strategic Industry Positioning
Major companies operating in the hyperimmune globulins market are Bayer AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Ltd., Fresenius Kabi AG, Grifols SA, Octapharma AG, Shanghai RAAS Blood Products Co. Ltd., Emergent BioSolutions Inc., Kedrion Biopharma Inc., LFB SA, Hualan Biological Engineering Inc., Taibang Biologic Group, Bio Products Laboratory (BPL) Ltd., ADMA Biologics, Cangene Corporation, Kamada Ltd., Saol Therapeutics Inc., Shire, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd.
Access The Complete Hyperimmune Globulins Market Report:
https://www.thebusinessresearchcompany.com/report/hyperimmune-globulins-global-market-report
Hyperimmune Globulins Market Largest Region: Which Geography Holds The Highest Market Share?
North Americawas the largest region in the hyperimmune globulins market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the hyperimmune globulins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
